Dr Waqas Ahmed.2r Khurram Shahzad,3r Iram Zehra
Non-motor symptoms are one of the reasons that overload the morbidity of Parkinson, it affects 1-2/1000 persons at any time. Its prevalence rate depends upon age and PD affects 1% of the population above 60 years. Non-motor symptoms (NMS) are the key elements to determine the quality of life of a patient. The evidence base treatments of PD with non-motor symptoms are substantial, under considerations to meet the quality treatment in recent years. Although, with high prevalence and disease adverse effects and limited options for treatment given have become a top priority to develop and tests the new methods for treatment of non-motor symptoms in PD. This review based on pharmacological and surgical intervention to treat the NMS in PD and previously reported inclusion criteria was used. The data obtained from more than 33 studies did not meet the randomized controlled inclusion criteria for anxiety rapid eye movement sleep disorder, excessive sweating, impaired olfaction, or ophthalmologic dysfunction. Each trial showed the specific score based on specific quality, concluded criteria used like possibly useful, insufficient evidence, possibly, if statistically proved no-significant used term negative and for clinically implication used investigational.